Back to search results

AAV2-hAADC Gene Therapy for Parkinson's Disease

This study is investigating a gene therapy called AAV2-hAADC for people with moderately-advanced Parkinson's Disease (PD) who experience motor fluctuations. AAV2-hAADC uses a modified virus (adeno-associated virus 2 or AAV2) to deliver genetic material that helps your brain produce more dopamine, a chemical often lacking in PD. The therapy is delivered directly to specific areas of the brain (the putamen and caudate). Researchers want to see if AAV2-hAADC is safe and if it can help improve symptoms. You may be eligible if you are an adult between 18 and 75 years old with an idiopathic PD diagnosis for over 3 years. The study will assess safety through side effects, MRI scans, physical exams, and lab tests over three years.

Study design
This is an interventional study with a planned enrollment of 9 participants. The phase of the study is not specified.
What's involved
Not specified in the trial record.
Compensation
Not stated in the trial record.
Follow-up
Participants will be followed for up to three years to monitor adverse events, and for six months for MRI findings.

AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.

NCT07267065

AAV2-hAADC for Parkinson's Disease (PDCS-01)

Not Yet Recruiting
PHASE1Ages 18–75InterventionalTreatment
Krzysztof Bankiewicz
~9 participants
Updated 2026-08-27 on ClinicalTrials.gov
What's tested:AAV2-hAADC

At a glance

Recruiting sites
0 of 1 listed site is recruiting right now
RecruitingSuspended, closed, or not yet open
What they're measuring
Adverse Events
Measured over Through 3 year Follow-up
+3 more outcomes measured

Conditions

Parkinson's Disease (PD)
Early Onset Parkinson Disease

Explore related trials

Parkinson Disease

NCT07267065

Where you'd take part

This study runs at 1 site. They're the same protocol — you choose where, and that choice sets who your contact draft is addressed to.

  • The Ohio State University

    Columbus, Ohiostudy coordinator listed

Sites open and close at different times, so the status above is per site — it can differ from the study's overall status.

Who to contact

Andrea Davis, MS
[email protected]
Email the study team

Opens a ready-to-send draft in your own email app — review before sending.

What this trial measures

  • Adverse EventsThrough 3 year Follow-up

    Assessment of AEs or SAEs and their relationship to the study procedure and study drug (graded as definite, probable, possible, unlikely, or unrelated).

  • MRI findingsThrough Month 6 Follow-up

    Intraoperative and post-operative MRI findings

  • Physical Exam and labsThrough 3 year Follow-up

    Changes from baseline in physical examination findings and routine clinical laboratory analysis (hematology, clinical chemistries, immunologic assessments).

  • C-SSRSThrough 3 year Follow-up

    Changes in Columbia-Suicide Severity Rating Scale (C-SSRS) results